WeTrials
Active, not recruiting

A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors

What is this study?

This study is testing a new experimental medication called AZD1390 combined with radiation therapy for adults with aggressive brain tumors. Researchers want to see how safe this combination is and how the body handles the new medicine.

Who can participate?

This trial is for adults with a confirmed diagnosis of certain aggressive brain tumors, such as glioblastoma. Participants must be able to care for most of their personal needs and meet specific medical and health history requirements.

What will happen?

Participants will receive the investigational drug AZD1390 alongside radiation therapy to treat their brain tumor. Doctors will closely monitor their safety, track how the drug moves through the body, and perform regular brain scans.

Where and when?

This study takes place at medical centers in locations including Boston and New York. The study is currently active but is not looking for new participants at this time.

Key Points
  • 1Tests a new brain tumor drug called AZD1390 combined with radiation.
  • 2Designed primarily to check the safety and side effects of the treatment.
  • 3Currently active at select locations in the United States, though not recruiting new patients.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Recurrent Glioblastoma MultiformePrimary Glioblastoma MultiformeBrain Neoplasms, MalignantLeptomeningeal Disease (LMD)

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.